Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension

Journal of Hypertension

Volumn 20, Issue 11, 2002, Pages 2257-2267

  Bakris, George ^a   Calhoun, David ^b   Egan, Brent ^c   Hellmann, Christopher ^d   Dolker, Michael ^d   Kingma, Iris ^d  

^a RUSH UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

Author keywords

Antihypertensive medication; Cardiovascular risk; Hypertension; Lipase inhibitor; Lipid profile; Obesity; Orlistat; Overweight; Trial; Weight loss

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TETRAHYDROLIPSTATIN; ANTIHYPERTENSIVE AGENT; ANTIOBESITY AGENT; LACTONE; LIPID;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CALORIC RESTRICTION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERTENSION; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEATORRHEA; THORAX PAIN; TREATMENT OUTCOME; WEIGHT REDUCTION; BLOOD; BLOOD PRESSURE; CALORIC INTAKE; DRUG EFFECT; MIDDLE AGED;

ANTI-OBESITY AGENTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; ENERGY INTAKE; FEMALE; HUMANS; HYPERTENSION; LACTONES; LIPIDS; MALE; MIDDLE AGED; OBESITY; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 0036854640     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200211000-00026     Document Type: Article

References (80)

1. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Monson RR, et al. A prospective study of obesity and risk of coronary heart disease in women [see comments]. N Engl J Med 1990; 322:882-889.
2. Rexrode KM, Hennekens CH, Willett WC, Colditz GA, Stampfer MJ, Rich-Edwards JW, et al. A prospective study of body mass index, weight change, and risk of stroke in women. JAMA 1997; 277:1539-1545.
3. Solomon CG, Manson JE. Obesity and mortality: A review of the epidemiologic data. Am J Clin Nutr 1997; 66:1044S-1050S.
4. National Heart, Lung and Blood Institute. Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults: The Evidence Report. Rockville, Maryland: National Institutes of Health; 1998.
5. World Health Organization. Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation of Obesity. Geneva: World Health Organization Division of Noncommunicable Diseases, Nutrition and Food Safety; 1997.
6. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: Prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998; 22:39-47.
7. Stamler J. Epidemic obesity in the United States [see comments]. Arch Intern Med 1993; 153:1040-1044.
8. Rippe JM, Crossley S, Ringer R. Obesity as a chronic disease: Modern medical and lifestyle management. J Am Diet Assoc 1998; 98:S9-15.
9. Huang Z, Willett WC, Manson JE, Rosner B, Stampfer MJ, Speizer FE, et al. Body weight, weight change, and risk for hypertension in women [see comments]. Ann Intern Med 1998; 128:81-88.
10. Yong LC, Kuller LH, Rutan G, Bunker C. Longitudinal study of blood pressure: Changes and determinants from adolescence to middle age. The Dormont High School follow-up study, 1957-1963 to 1989-1990. Am J Epidemiol 1993; 138:973-983.
11. Jones DW, Kim JS, Andrew ME, Kim SJ, Hong YP. Body mass index and blood pressure in Korean men and women: The Korean National Blood Pressure Survey. J Hypertens 1994; 12:1433-1437.
12. Scaglione R, Parrinello G, Corrao S, Ganguzza A, Di Chiara T, Arnone S, et al. Prevalence of obesity and ischaemic heart disease in hypertensive subjects. Eur Rev Med Pharmacol Sci 1997; 1:69-75.
13. Smith AC, Villarosa IP. Yakovlevitch M, Bakris GL, Elliott WJ, Neri G, Black H. Resistant hypertension in a tertiary care clinic: Revisited. Am J Hypertens 2000; 13:112A.
14. Kannel WB. Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens 2000; 14:83-90.
15. Mikhail N, Golub MS, Tuck ML. Obesity and hypertension. Prog Cardiovasc Dis 1999; 42:39-58.
16. Huang Z, Reddy A. Weight change, ideal weight and hypertension. Curr Opin Nephrol Hypertens 1999; 8:343-346.
17. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure [see comments]. Arch Intern Med 1997; 157:2413-2446 [published erratum appears in Arch Intern Med 23 March 1998; 158 (6):573].
18. Isles CG, Walker LM, Beevers GD, Brown I, Cameron HL, Clarke J, et al. Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens 1986; 4:141-156.
19. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group [see comments]. Lancet 1998; 351:1755-1762.
20. Stevens VJ, Corrigan SA, Obarzanek E, Bernauer E, Cook NR, Hebert P, et al. Weight loss intervention in phase 1 of the Trials of Hypertension Prevention. The TOHP Collaborative Research Group. Arch Intern Med 1993; 153:849-858.
21. He J, Whelton PK, Appel LJ, Charleston J, Klag MJ. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 2000; 35:544-549.
22. Jones DW, Miller ME, Wofford MR, Anderson DC Jr, Cameron ME, Willoughby DL, et al. The effect of weight loss intervention on antihypertensive medication requirements in the Hypertension Optimal Treatment (HOT) study. Am J Hypertens 1999; 12:1175-1180.
23. Campbell NR, Burgess E, Choi BC, Taylor G, Wilson E, Cleroux J, et al. Lifestyle modifications to prevent and control hypertension. 1. Methods and an overview of the Canadian recommendations. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. Can Med Assoc J 1999; 160:S1-S6.
24. Blumenthal JA, Sherwood A, Gullette EC, Babyak M, Waugh R, Georgiades A, et al. Exercise and weight loss reduce blood pressure in men and women with mild hypertension: Effects on cardiovascular, metabolic, and hemodynamic functioning [in process citation]. Arch Intern Med 2000; 160:1947-1958.
25. Davis BR, Blaufox MD, Oberman A, Wassertheil-Smoller S, Zimbaldi N, Cutler JA, et al. Reduction in long-term antihypertensive medication requirements. Effects of weight reduction by dietary intervention in overweight persons with mild hypertension. Arch Intern Med 1993; 153:1773-1782.
26. Mulrow CD, Chiquette E, Angel L, Cornell J, Summerbell C, Anagnostelis B, et al. Dieting to reduce body weight for controlling hypertension in adults. Cochrane Database Syst Rev 2000; CD000484.
27. McCarron DA, Reusser ME. Body weight and blood pressure regulation. Am J Clin Nutr 1996; 63:423S-425S.
28. Dustan HP, Weinsier RL. Treatment of obesity-associated hypertension. Ann Epidemiol 1991; 1:371-379.
29. Darne B, Nivarong M, Tugaye A, Safar M, Plouin PF, Guillanneuf MT, et al. Hypocaloric diet and antihypertensive drug treatment. A randomized controlled clinical trial. Blood Press 1993; 2:130-135.
30. Oberman A, Wassertheil-Smoller S, Langford HG, Blaufox MD, Davis BR, Blaszkowski T, et al. Pharmacologic and nutritional treatment of mild hypertension: Changes in cardiovascular risk status [see comments]. Ann Intern Med 1990; 112:89-95.
31. Reisin E, Abel R, Modan M, Silverberg DS, Eliahou HE, Modan B. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N Engl J Med 1978; 298:1-6.
32. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981; 304:930-933.
33. Rissanen A, Pietinen P, Siljamaki-Ojansuu U, Piirainen H, Reissel P. Treatment of hypertension in obese patients: Efficacy and feasibility of weight and salt reduction programs. Acta Med Scand 1985; 218:149-156.
34. Singh RB, Niaz MA, Bishnoi I, Singh U, Begum R, Rastogi SS. Effect of low energy diet and weight loss on major risk factors, central obesity and associated disturbances in patients with essential hypertension. J Hum Hypertens 1995; 9:355-362.
35. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled trial [see comments]. JAMA 1999; 281:235-242 [published erratum appears in JAMA 7 April1999; 281 (13):1174].
36. Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: A randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000; 24:306-313
37. Hill JO, Hauptman J, Anderson JW, Fujioka K, O'Neil PM, Smith DK, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: A 1-y study [see comments]. Am J Clin Nutr 1999; 69:1108-1116.
38. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000; 8:49-61.
39. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group [see comments]. Lancet 1998; 352:167-172.
40. Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160:1321-1326.
41. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998; 21:1288-1294.
42. Zavoral JH. Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertens 1998; 16:2013-2017.
43. National Cholesterol Education Program. Report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988; 148:36-69.
44. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994; 89:1333-1445.
45. National Cholesterol Education Program. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
46. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-1847.
47. Weber C, Tam YK, Schmidtke-Schrezenmeier G, Jonkmann JH, van Brummelen P. Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers. Eur J Clin Pharmacol 1996; 51:87-90.
48. Heymsfield S, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160:1321-1326.
49. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled. JAMA 1999; 281 (3):235-242.
50. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999; 106:179-184.
51. Wirth A, Krause J. Long-term weight loss with sibutramine: A randomized controlled trial. JAMA 2001; 286:1331-1339.
52. Vidgren HM, Agren JJ, Valve RS, Karhunen LJ, Rissanen AM, Uusitupa MI. The effect of orlistat on the fatty acid composition of serum lipid fractions in obese subjects. Clin Pharmacol Ther 1999; 66:315-322.
53. Tonstad S, Pometta D, Erkelens DW, Ose L, Moccetti T, Schouten JA, et al. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol 1994; 46:405-410.
54. Stevens VJ, Obarzanek E, Cook NR, Lee IM, Appel LJ, Smith West D, et al. Long-term weight loss and changes in blood pressure: Results of the Trials of Hypertension Prevention, Phase II. Ann Intern Med 2001; 134:1-11.
55. Kolanowski J. Obesity and hypertension: From pathophysiology to treatment. Int J Obes Relat Metab Disord 1999; 23 (suppl. 1):42-46.
56. Julius S, Valentini M, Palatini P. Overweight and hypertension: A 2-way street? Hypertension 2000; 35:807-813.
57. Goodfriend TL Egan BM, Kelley DE. Aldosterone in obesity. Endocr Res 1998; 24:789-796.
58. Cooper R, Forrester T, Ogunbiyi O, Muffinda J. Angiotensinogen levels and obesity in four black populations. ICSHIB Investigators. J Hypertens 1998; 16:571-575.
59. Krieger DR, Landsberg L. Mechanisms in obesity-related hypertension: Role of insulin and catecholamines. Am J Hypertens 1988; 1:84-90.
60. Reaven GM, Hoffman BB. Hypertension as a disease of carbohydrate and lipoprotein metabolism. Am J Med 1989; 87:2S-6S.
61. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - The role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334:374-381.
62. Katzmarzyk PT, Perusse L, Rao DC, Bouchard C. Spousal resemblance and risk of 7-year increases in obesity and central adiposity in the Canadian population. Obes Res 1999; 7:545-551.
63. Chisholm DJ, Campbell LV, Kraegen EW. Pathogenesis of the insulin resistance syndrome (syndrome X). Clin Exp Pharmacol Physiol 1997; 24:782-784.
64. Bittencourt LR, Moura SM, Bagnato MC, Gregorio LC, Tufik S, Nery LE. Assessment of ventilatory neuromuscular drive in patients with obstructive sleep apnea. Braz J Med Biol Res 1998; 31:505-513.
65. Neel JV, Julius S, Weder A, Yamada M, Kardia SL, Haviland MB. Syndrome X: Is it for real? Genet Epidemiol 1998; 15:19-32.
66. Baron AD. Hemodynamic actions of insulin. Am J Physiol 1994; 267:E187-E202.
67. Ogawa Y, Masuzaki H, Hosoda K, Aizawa-Abe M, Suga J, Suda M, et al. Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin. Diabetes 1999; 48:1822-1829.
68. Grandi AM, Zanzi P, Fachinetti A, Gaudio G, Ceriani L, Bertolini A, et al. Insulin and diastolic dysfunction in lean and obese hypertensives: Genetic influence. Hypertension 1999; 34:1208-1214.
69. McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: A 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000; 160:2185-2191.
70. Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. Int J Obes Relat Metab Disord 2000; 24:144-150.
71. Luque CA, Rey JA. Sibutramine: A serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother 1999; 33:968-978.
72. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, et al. Sibutramine produces dose-related weight loss. Obes Res 1999; 7:189-198.
73. Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res 1996; 4:263-270.
74. McNeely W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs 1998; 56:1093-1124.
75. American Head Association urges caution on new diet drug [news]. Circulation 1998; 97:B3.
76. Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P. Efficacy and tolerability of sibutramine in obese patients: A dose-ranging study. Int J Obes Relat Metab Disord 1998; 22:32-38.
77. Quesenberry CP Jr, Caan B, Jacobson A. Obesity, health services use, and health care costs among members of a health maintenance organization. Arch Intern Med 1998; 158:466-472.
78. Heithoff KA, Cuffel BJ, Kennedy S, Peters J. The association between body mass and health care expenditures. Clin Ther 1997; 19:811-820.
79. Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States [see comments]. Obes Res 1998; 6:97-106.
80. Greenway FL, Ryan DH, Bray GA, Rood JC, Tucker EW, Smith SR. Pharmaceutical cost savings of treating obesity with weight loss medications. Obes Res 1999; 7:523-531.